TrialBlood advances2020

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Stephen T Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.